Hemostemix Closes $469,366 Private Placement
Hemostemix (OTCQB: HMTXF) has successfully closed a non-brokered private placement offering, raising CAD $469,366 through the issuance of 3,911,385 Common Shares at CAD $0.12 per share. The TSX Venture Exchange has granted conditional approval for this offering.
The funds will be directed towards general working capital, operational expenses, and business development activities. The issued securities are subject to a four-month hold period under Canadian securities laws. The investor is confirmed to be arm's length to the company and not a Related Party.
Hemostemix (OTCQB: HMTXF) ha completato con successo un'offerta privata senza intermediari, raccogliendo 469.366 CAD tramite l'emissione di 3.911.385 Azioni Ordinarie a 0,12 CAD per azione. La TSX Venture Exchange ha concesso l'approvazione condizionata per questa offerta.
I fondi saranno destinati al capitale circolante generale, alle spese operative e alle attività di sviluppo commerciale. I titoli emessi sono soggetti a un periodo di blocco di quattro mesi secondo la normativa canadese sui valori mobiliari. L'investitore è confermato come estraneo alla società e non come Parte Correlata.
Hemostemix (OTCQB: HMTXF) ha cerrado con éxito una colocación privada sin intermediarios, recaudando 469,366 CAD mediante la emisión de 3,911,385 Acciones Comunes a 0.12 CAD por acción. La Bolsa de Valores TSX Venture ha otorgado la aprobación condicional para esta oferta.
Los fondos se destinarán a capital de trabajo general, gastos operativos y actividades de desarrollo empresarial. Los valores emitidos están sujetos a un período de retención de cuatro meses conforme a las leyes de valores canadienses. Se confirma que el inversor es independiente de la empresa y no es una Parte Relacionada.
Hemostemix (OTCQB: HMTXF)는 중개인 없이 사모 발행을 성공적으로 마무리하여 CAD $469,366를 모금하였으며, 3,911,385 보통주를 주당 CAD $0.12에 발행하였습니다. TSX 벤처 거래소는 이 발행에 대해 조건부 승인을 부여하였습니다.
자금은 일반 운전자본, 운영비용 및 사업 개발 활동에 사용될 예정입니다. 발행된 증권은 캐나다 증권법에 따라 4개월간의 보호예수 기간이 적용됩니다. 투자자는 회사와 독립적이며 관련 당사자가 아님이 확인되었습니다.
Hemostemix (OTCQB : HMTXF) a clôturé avec succès une offre privée sans intermédiaire, levant 469 366 CAD par l'émission de 3 911 385 actions ordinaires au prix de 0,12 CAD par action. La TSX Venture Exchange a accordé une approbation conditionnelle pour cette offre.
Les fonds seront affectés au fonds de roulement général, aux dépenses opérationnelles et aux activités de développement commercial. Les titres émis sont soumis à une période de blocage de quatre mois conformément aux lois canadiennes sur les valeurs mobilières. L'investisseur est confirmé comme indépendant de la société et n'est pas une partie liée.
Hemostemix (OTCQB: HMTXF) hat erfolgreich eine nicht vermittelte Privatplatzierung abgeschlossen und dabei CAD $469.366 durch die Ausgabe von 3.911.385 Stammaktien zu je CAD $0,12 pro Aktie eingenommen. Die TSX Venture Exchange hat eine bedingte Genehmigung für dieses Angebot erteilt.
Die Mittel werden für das allgemeine Betriebskapital, Betriebsausgaben und Geschäftsentwicklungsaktivitäten verwendet. Die ausgegebenen Wertpapiere unterliegen gemäß kanadischem Wertpapierrecht einer viermonatigen Haltefrist. Der Investor ist nachweislich unabhängig vom Unternehmen und keine verbundene Partei.
- Secured CAD $469,366 in new capital funding
- Obtained TSXV conditional approval for the offering
- Strengthened working capital position for operations and business development
- Potential dilution for existing shareholders through issuance of 3,911,385 new shares
- Shares issued at relatively low price of CAD $0.12
Calgary, Alberta--(Newsfile Corp. - July 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that the TSX Venture Exchange ("TSXV") conditionally approved the Company's previously disclosed non-brokered private placement (the "Offering") in the amount of CAD
As per TSXV Policy 4.1, the investor is arm's length to the Company and is not a Related Party to the Company at the time of disclosure.
The use of proceeds will be allocated to general working capital purposes, supporting the Company's continuing operational expenses and business development activities.
The Company confirms that there is no material fact or material change about the Company that has not been generally disclosed.
All securities issued in connection with the Offering are subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.
ABOUT HEMOSTEMIX
Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in ten peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of
For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder: EM: tsmeenk@hemostemix.com / PH: 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the Closing of a non brokered private placement, in furtherance of sales in Florida of VesCell (ACP-01), and the commercialization of ACP-01 via the sale of compassionate treatments under Florida SB 1768. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/257821
FAQ
How much did Hemostemix (HMTXF) raise in their July 2025 private placement?
What is the share price for Hemostemix's July 2025 private placement?
How many new shares did Hemostemix (HMTXF) issue in the July 2025 offering?
What will Hemostemix use the private placement proceeds for?
What restrictions apply to the shares issued in Hemostemix's private placement?
